Site Search
Displaying results 1 - 10 of 573
Resource | Reviews and Snapshots,
Marked inequalities and diverse epidemic trends affect progress in the HIV response in Asia and the Pacific. The HIV epidemic in the region disproportionately affects people from key populations, especially young people (aged 15–24 years), and their sexual partners. Download the regional factsheet to find out the most up-to-date HIV info, data and analysis.
Resource | Presentations,
UNAIDS new Global AIDS Update report shows 29.8 million of the 39 million [33.1 million–45.7 million] people living with HIV globally are receiving life-saving treatment. An additional 1.6 million people received HIV treatment in each of 2020, 2021 and 2022.
Resource | Publications,
This report marks the end of the early implementation phase of GLASS. In addition to presenting data collected through the latest data call, this report provides a summary of five years of national AMR surveillance data contributed to GLASS from its initiation, presents AMR findings in the context of progress of country participation in GLASS and in global AMR surveillance coverage and laboratory quality assurance systems at (sub)national level.
Resource | Publications,
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resistance in adults, children and adolescents receiving dolutegravir-based ART.
This sentinel method is implemented complementary to WHO-recommended methods for estimating nationally representative levels of acquired HIV drug resistance.
Resource | Publications,
This publication is primarily intended for national and local policy-makers; global, regional, country and local programme implementers; organizations working in and providers of health, HIV, mental health and other relevant services; civil society; and community-based and community-led organizations and advocates. It brings together and refers to existing HIV and mental health, psychosocial support and other service provision guidelines, recommendations and tools, including the World Health Organization (WHO) Mental Health Gap Action Programme (mhGAP) mhGAP intervention guide and mhGAP operations manual; WHO, United Nations Office on Drugs and Crime and other guidelines and tools related to substance use; and WHO consolidated guidelines, tools and resources on HIV testing, prevention, treatment and care.
Resource | Infographics,
Human Papilloma Virus (HPV) is the most common sexually transmitted infection, and two types of HPV (16 and 18) cause nearly 50% of high-grade cervical pre-cancers. HIV and cervical cancer are inextricably linked. Women living with HIV are six times more likely to develop cervical cancer, which is one of the AIDS-defining illnesses and the most common cancer among women living with HIV globally. Cervical cancer is a preventable, curable disease and can be eliminated as a public health problem with primary and secondary prevention, treatment, and care of cervical cancer, in combination with addressing social, health and other inequalities and integrated approaches.
Resource | Publications,
As part of HIV prevention and care continuum HTS, ART service, and STI service have been strengthened aiming to ensure broader coverage especially amongst KPs. By doing so, a number of initiatives have been applied and expanded such as community testing, self-testing, multi-month dispensing, etc. In the middle of 2019, PrEP has been introduced with the aim to prevent new infection amongst high risk KPs. While originally established as facility-based intervention, the same day PrEP delivery by community-based organizations has also been applied recently in order to further expand the scope and coverage of such service amongst high risk KPs.
Resource | Guidelines,
Hepatitis C virus (HCV) infection is a major public health problem and cause of chronic liver disease that leads to approximately 399 000 deaths annually. In 2019, only 21% of the 58 million persons with chronic HCV infection had been diagnosed, and 13%, treated.
These guidelines provide updated evidence-based recommendations on the priority HCV-related topics from the 2018 WHO Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection and the 2017 WHO Guidelines on hepatitis B and C testing.
Resource | Guidelines,
National Guideline on HIV testing and treatment 2022 introduces new standards for viral load testing and viral load suppression. The guidelines also stress on community-based care of PLHIV with differentiated care approach which means less hospital visits for healthy PLHIV and more time to provide for critical patients.
Resource | Publications,
A series of country pilots (Brazil, Egypt, Georgia, Mongolia, Rwanda, Thailand and United Kingdom of Great Britain and Northern Ireland) of the elimination criteria across the six WHO regions was undertaken during 2021–2022. The main objective was to conduct a practical assessment and evaluate the feasibility of accurately measuring the impact and programmatic targets for hepatitis elimination as established by the WHO Interim guidance for country validation of viral hepatitis elimination.